He said, however, that the investigation was continuing to ensure that the problems, described as a shortage of raw materials, were not a result of AstraZeneca allegedly favouring the UK’s order for 100m doses.
De Croo said: “AstraZeneca pointed to production issues at Seneffe. The federal medicines and health products agency has together with its European partners carried out checks at the site.
“It appears that there is a shortage of the raw materials needed to make the vaccines. The analysis of the situation there is still ongoing.
Love to know which raw materials. And what’s the hold up on them? Because allow it go go a level or two deeper and we end up back where home production just isn’t possible. Because at some level of detail the supply chain for anything and everything is the entire global economy.